BioSpace News Archive

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that at the special meeting of stockholders, held September 28, 2018

The award has a maximum value of $7,000,000 USD over five years, with an initial procurement in excess of $600,000 USD.

Medivir AB today announced safety and efficacy data following an interim analysis of phase I data from the ongoing phase I/II study of birinapant in combination with MSD’s anti-PD-1 therapy, Keytruda®.

Baloxavir marboxil - a first-in-class, single-dose, investigational oral medicine - is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable to serious influenza complications

Phase 1 clinical program for PXL770 was observed to have a favorable pharmacokinetic, tolerability and safety profile

All doses were safe and well-tolerated

-Due to large backlog of applications, the Notified Body, LNE/G-MED, now expects completion of the process around year’s end

Axcelead Drug Discovery Partners, Inc. announced today a non-exclusive license agreement to provide Axcelead with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property to enhance their drug discovery service offering. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology.

NeuroVive Pharmaceutical AB today announced the successful completion of biomarker analyses of samples from its clinical study in severe traumatic brain injury patients (the CHIC study) using the company’s investigational compound NeuroSTAT.

Cerecin announces first close of a new investment round and establishment of new global HQ in Singapore